International law firm McDermott Will & Emery represented Zura Bio Limited, a clinical-stage biotechnology company focused on developing novel medicines for immune disorders, in its definitive business combination with JATT Acquisition Corp (NYSE: JATT, JATT.U, JATT.WS), a publicly traded special purpose acquisition (SPAC) company. Upon closing of the transaction, the combined company will be renamed “Zura Bio Limited”, and the company’s ordinary shares and warrants are expected to be listed on the NYSE under the ticker symbol “ZURA.”

• The transaction was announced on June 17, 2022 and is expected to be completed in the fourth quarter of 2022.
• Proceeds from the transaction are expected to provide Zura Bio with the capital needed to accelerate the development of ZB-168, a fully-human, clinical-stage antibody targeting IL7Rα. ZB-168 is the only anti-IL7Rα antibody to have reported data in patients with an autoimmune disease. In a 37-patient phase 1b trial in type1 diabetes mellitus, ZB-168 has demonstrated a favorable safety profile as well as the ability to modulate key T-cell subpopulations.
• The McDermott cross-borders team was led by Ari Edelman, Gary Howes and Siddhartha Sivaramakrishnan and included Phillip Corser, Steven Hadjilogiou, Eric Klee, Beth Kuhn, Daniel McGuire, James Ross, Brian Tratner and Andrew Liazos.
• Read Zura Bio and JATT Acquisition’s combined press release.

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.